GlassScriptPhysician profile
Man Q Le
NPI 1457302580
$6,938.70
in general payments reported to CMS, 2019-2025
35 companies · $452 in 2025
The $452 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $119 · 2021: $373 · 2022: $670 · 2023: $3,459 · 2024: $1,080 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,572 · Food and Beverage: $2,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,572.04 |
| Food and Beverage | $2,419.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $2,023.56 | 2023-2024 | Evoke Scs, Evoke |
| Pacira Pharmaceuticals Incorporated | $1,410.09 | 2023 | Iovera |
| Abbott Laboratories | $1,319.93 | 2019-2023 | Proclaim |
| Boston Scientific Corporation | $589.21 | 2020-2025 | Intracept |
| Medtronic, INC. | $352.59 | 2022-2025 | Inceptiv |
| Vertos Medical, INC. | $178.91 | 2022-2024 | Mild Device Kit |
| Ucb, INC. | $84.74 | 2023-2025 | Briviact |
| Abbvie INC. | $80.86 | 2024 | |
| Merz Pharmaceuticals, LLC | $80.73 | 2024-2025 | Inbrija, Xeomin, Ampyra |
| Forte Bio-Pharma LLC | $69.60 | 2020-2022 | |
| Spr Therapeutics, INC | $60.72 | 2025 | Sprint Pns System |
| Biodelivery Sciences International, INC. | $59.42 | 2019-2020 | |
| Argenx US, INC. | $56.44 | 2023-2024 | Vyvgart Hytrulo |
| Tg Therapeutics, INC. | $46.02 | 2024 | |
| Kyowa Kirin, INC. | $41.69 | 2024 | Nourianz |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $38.48 | 2023 | Adlarity |
| Collegium Pharmaceutical, INC. | $37.16 | 2019 | |
| Lilly USA, LLC | $34.55 | 2023 | Amyvid |
| Stimwave Technologies Incorporated | $29.70 | 2019-2021 | |
| Neurelis, INC. | $29.43 | 2024-2025 | Valtoco |
| Kaleo, INC. | $27.08 | 2019 | |
| Mdd US Operations, LLC | $25.54 | 2019 | |
| Eisai INC. | $24.65 | 2024 | |
| Amneal Pharmaceuticals LLC | $24.25 | 2025 | Crexont |
| Integra Lifesciences Corporation | $24.16 | 2024 | Codman Hakim, Codman Certas, Cusa Clarity |
| Alexion Pharmaceuticals, INC. | $22.64 | 2024 | Soliris |
| Assertio Therapeutics, INC. | $22.47 | 2019 | |
| Arbor Pharmaceuticals, INC. | $22.12 | 2019 | |
| Zyla Life Sciences, INC. | $20.68 | 2020 | |
| Csl Behring | $18.25 | 2023 | Hizentra |
| Stryker Corporation | $18.18 | 2024 | Mild Device Kit |
| Biogen, INC. | $17.66 | 2025 | Skyclarys |
| Medtronic USA, INC. | $17.12 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.32 | 2019 | |
| Nevro Corp. | $13.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Man Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.